canertinib dihydrochloride has been researched along with Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansari, RH; Kugler, JW; Richards, JM; Ryan, CW; Shulman, KL; Sosman, JA; Vogelzang, NJ; Vokes, EE | 1 |
| Didolkar, MS; Eckardt, JR; Flaherty, LE; Samlowski, W; Sondak, VK; Taylor, SA; Unger, JM; Whitehead, RP | 1 |
2 trial(s) available for canertinib dihydrochloride and Melanoma
| Article | Year |
|---|---|
CI-980 in advanced melanoma and hormone refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbamates; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Prostatic Neoplasms; Pyrazines; Pyridines | 2000 |
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Pyrazines; Pyridines; Skin Neoplasms; Survival Rate; Treatment Outcome | 2001 |